Findings

What do systematic reviews say?

1,793 questions · 1,866 findings · 339 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 245 · 13.1%GRADE not reported 142 · 7.6%Very low 612 · 32.8%Low 513 · 27.5%Moderate 305 · 16.3%High 49 · 2.6%

Femoral vs subclavian insertion: short‐term catheterization

Catheter‐related thrombotic complications · critically ill patients

Femoral leads to higher catheter‐related thrombotic complications compared with subclavian insertion: short‐term catheterization (high certainty).

1 finding from 1 review

Central venous access sites for the prevention of venous thrombosis, stenosis and infection 2012 · Cochrane Headline outcomes only
RR 11.53 [2.8, 47.52]
1 study · 223 participants
High

Single‐dose vs short duration antibiotics

Persistent bacteriuria · children with lower urinary tract infection

It is very uncertain whether single‐dose changes persistent bacteriuria compared with short‐course (3‐7 days) antibiotics (very low certainty).

1 finding from 1 review

Antibiotics for treating lower urinary tract infection in children 2012 · Cochrane Headline outcomes only
RR 1.3 [0.65, 2.62]
2 studies · 145 participants
Very low

Single‐dose vs short duration antibiotics

Recurrence · children with lower urinary tract infection

It is very uncertain whether single‐dose changes recurrence compared with short‐course (3‐7 days) antibiotics (very low certainty).

1 finding from 1 review

Antibiotics for treating lower urinary tract infection in children 2012 · Cochrane Headline outcomes only
RR 1.5 [0.43, 5.26]
2 studies · 145 participants
Very low

Single‐dose vs short duration antibiotics

Re‐infection · children with lower urinary tract infection

It is very uncertain whether single‐dose changes re‐infection compared with short‐course (3‐7 days) antibiotics (very low certainty).

1 finding from 1 review

Antibiotics for treating lower urinary tract infection in children 2012 · Cochrane Headline outcomes only
RR 0.16 [0.02, 1.26]
1 study · 45 participants
Very low

Whole body vibration vs an active physical therapy (short‐term effects)

Balance ( · patients with neurodegenerative disease

1 finding from 1 review

Whole‐body vibration training for patients with neurodegenerative disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 45 participants
Low

Whole body vibration vs an active physical therapy (short‐term effects)

Gait Timed Up and Go test · patients with neurodegenerative disease

1 finding from 1 review

Whole‐body vibration training for patients with neurodegenerative disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 45 participants
Low

Fixed dental prosthesis (cantilever FDP) vs Removable dental prosthesis (RDP)

Caries incidence (2 years) · Patients with a shortened dental arch (missing posterior teeth)

Fixed dental prosthesis (cantilever FDP) led to lower caries incidence (2 years) compared with removable dental prosthesis (RDP); GRADE not reported.

1 finding from 1 review

Interventions for replacing missing teeth: partially absent dentition 2012 · Cochrane All outcomes
2 years
RR 0.43 [0.21, 0.87]
1 study · 50 participants
GRADE not reported

Fixed dental prosthesis (cantilever FDP) vs Removable dental prosthesis (RDP)

Patient satisfaction with prosthesis · Patients with a shortened dental arch (missing posterior teeth)

Fixed dental prosthesis (cantilever FDP) showed no clear difference in patient satisfaction with prosthesis compared with removable dental prosthesis (RDP); GRADE not reported.

1 finding from 1 review

Interventions for replacing missing teeth: partially absent dentition 2012 · Cochrane All outcomes
RR 1.22 [0.99, 1.51]
1 study · 54 participants
GRADE not reported

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Infant HIV Transmission or Death at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant HIV Transmission or Death at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.66 [0.43, 1]
1 study · 795 participants
Low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Mother to Child Transmission at Birth · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at Birth compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.78 [0.29, 2.07]
1 study · 805 participants
Low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Mother to Child Transmission at 6 Weeks · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora continued: AZT/3TC/LPV‐r showed no clear difference in mother to Child Transmission at 6 Weeks compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.69 [0.34, 1.37]
1 study · 789 participants
Low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Mother to Child Transmission at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora continued: AZT/3TC/LPV‐r may leads to lower mother to Child Transmission at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.56 [0.33, 0.99]
1 study · 776 participants
Low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Mother to Child Transmission at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora continued: AZT/3TC/LPV‐r changes mother to Child Transmission at 12 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.58 [0.34, 0.97]
1 study · 761 participants
Very low

Bae: AZT/3TC/NVP vs Short Course AZT/sdNVP

Maternal Resistance · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether lehman: AZT/3TC/NVP changes maternal Resistance compared with short Course AZT/sdNVP (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.24 [0.07, 0.88]
1 study · 27 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

HIV Transmission or Death at 12 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

It is very uncertain whether kesho Bora: AZT/3TC/LPV‐r changes infant HIV Transmission or Death at 12 months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.64 [0.44, 0.92]
1 study · 765 participants
Very low

Kesho Bora: AZT/3TC/LPV‐r vs Short‐Course AZT (intrapartum AZT/3TC/sd‐NVP)

Infant Mortality at 6 Months · HIV‐infected Pregnant Women With CD4 Counts 200‐500 Cells/mm3

Kesho Bora: AZT/3TC/LPV‐r showed no clear difference in infant Mortality at 6 Months compared with short‐Course AZT (intrapartum AZT/3TC/sd‐NVP) (moderate certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.78 [0.43, 1.42]
1 study · 781 participants
Moderate

Bae: AZT/3TC/NVP vs Other Short Course PMTCT Regimen

Stillbirth · ART‐Eligible HIV‐infected Pregnant Women

It is very uncertain whether ekouevi: AZT/3TC/NVP changes stillbirths compared with other Short Course PMTCT Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.16 [0.34, 3.93]
1 study · 326 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course PMTCT Regimen

Low birthweight · ART‐Eligible HIV‐infected Pregnant Women

It is very uncertain whether ekouevi: AZT/3TC/NVP changes infant Low Birth Weight compared with other Short Course PMTCT Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.81 [1.09, 3]
1 study · 309 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course PMTCT Regimen

Mother to Child Transmission at 12 Months · ART‐Eligible HIV‐infected Pregnant Women

It is very uncertain whether ekouevi: AZT/3TC/NVP changes mother to Child Transmission at 12 Months compared with other Short Course PMTCT Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.14 [0.04, 0.47]
1 study · 311 participants
Very low

Bae: AZT/3TC/NVP vs Other Short Course Regimen

HIV Transmission or Death at 1 Month · HIV‐infected pregnant women

It is very uncertain whether tonwe‐Gold: AZT/3TC/NVP changes HIV Transmission or Death at 1 Month compared with other Short Course Regimen (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.86 [0.25, 2.97]
1 study · 218 participants
Very low